Blog
The “Proportionate Approach Route” for Technology Appraisal by NICE
The innovation of the new treatments has outpaced the rate at which NICE (The National Institute for Health and Care Excellence) appraises the treatments via its existing method of appraisal. NICE recently announcing taking a “proportionate approach” to technology appraisals is a landscape change ensuring faster guidance and efficiency gains.
Real World Evidence: From Vision to Reality
Framework of Developing Real world Evidence (RWE) There has been a burgeoning bid about the use of Real-World data in healthcare. The National Institute for Health and Care Excellence (NICE) has released the NICE real-world evidence framework on 23rd June 2022 which...
Cost of war on Global Health: A short commentary
Although conflicts have existed since the beginning of human civilization, 21st century saw a surge in mass violence, wars, genocide and continued conflict. In 2008 alone, 345 conflicts were ongoing worldwide, of which 134 (39%) involved large-scale violence resulting in millions of deaths.
Antimicrobial Resistance: A threat to the world! But, how does the UK’s ‘Netflix-style’ payment model appeal to roll out new antimicrobials and combat AMR?
This blog covers the latest developments in the Antimicrobial Resistance (AMR) space and how the UK’s recently approved ‘Netflix-style’ subscription-based payment model can work as an example to the world to reverse the decline in the antibiotics category.
Blockchain in Healthcare
No matter how reliable a brand is: from manufacturer to retailer there could be at least 6 different parties (manufacturer, packer, mover, chain of distributors, wholesaler, retailer) who carried your product before it reached you. So is it the right time to change our idea of trust? This is exactly what a blockchain is trying to resolve everywhere. A trust issue.
How is your drug price determined? Game theory perspective to the pharmaceutical Industry
Who picks the price of a drug? Is it the market, the State, or the manufacturer? Medicines prices vary around the world and are the result of different processes and strategies. Depending upon the structure of the market, the price decision mechanism of drugs can fall under different types of games involving multiple players.
A brief history of health technology assessment: A historical ride and present story by Prof. Egon Jonsson (Webinar Notes & QnA)
ConnectHEOR hosted a webinar on 18th January 2022 by Professor Egon Jonsson on the topic “A brief history of health technology assessment: A historical ride and present story”. This blog captures the key points of the discussion in the webinar.
In times of COVID, let’s take a look at the previous 1918 pandemic
In times of COVID-19, let’s take a look at the 1918 pandemic, and compare that to the current situation. Perhaps, the world is very different now, but the pandemic was deadly then, and is deadly now. Almost two years into the current pandemic, and the world is still...
Is Pharmaceutical innovation pushing HTA in the UK? The Innovative Medicines Fund, UK
Updated on 30th July 2022 The guidelines for Innovative Medicines Fund (IMF) have been issued by NHS on June 6, 2022. The design of the IMF has been largely drawn on the lines of Cancer Drug Funds (CDF). Along with the guidelines, the responses to engagement on...
Think of data thieves as smart as Sherlock Holmes! Understanding Statistical Disclosure and Anonymisation
Imagine, you are taking a treatment for disease X, that nobody is aware except you and the doctor. In due course, a research agency (owned by the hospital management) collects your private information (regarding your disease and symptoms) assuring you that your...
Understanding health economics and outcomes research (HEOR) from a non-health economist lens!
Remember the dilemma of Alan Turing from the movie The Imitation Game where to optimize for a war winning strategy he happened to decide on the fate of American soldiers?Sometimes people have to play God as we have to accept the harsh truth of life that "everybody...